marked.bio

HER2 bispecific antibody · bispecific antibody

zanidatamab

1 active trials across 2 of our biomarkers, targeting HER2 (biparatopic). Not approved for any biomarker on marked.bio yet.

Also known as ZW25, Ziihera.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
MSI-H / dMMR 1 1 Phase 2
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 0 1 –

Trials

1 of 2 trials shown

  1. An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy

    Not yet recruiting Phase 2 Haihua Yuan Started 2026Primary completion 2029-12 NCT07631871

    zanidatamab

    anti-PD-L1 therapy for MSI-H/dMMR tumors if clinically indicated.

    MSI-H / dMMRNeoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm